Most Read Articles
4 days ago
A recent study has shown no improvement in the rate of blood pressure (BP) control despite an increase in the prevalence of antihypertensive medication use.
Roshini Claire Anthony, 11 Feb 2020

The consumption of processed meat or unprocessed red meat may be associated with a slightly elevated risk of incident cardiovascular disease (CVD)* and all-cause mortality, according to a US study.

29 Jan 2020
Several high-density lipoprotein (HDL) functionality parameters, which are linked to HDL roles on cholesterol metabolism, endothelial protection and antioxidant/anti-inflammatory defence, contribute to an increased risk of incident acute coronary syndromes and its manifestations in individuals at high risk of cardiovascular disease, a study reports.
Jairia Dela Cruz, 25 Nov 2019
Use of the PCSK9* inhibitor alirocumab in acute coronary syndrome (ACS) patients on a background of high-intensity statin treatment delivers reductions in total hospitalizations and death with corresponding gains in days alive and out of hospital (DAOH), according to the results of prespecified and posthoc analyses of the ODYSSEY OUTCOMES** trial presented at the American Heart Association (AHA) 2019 Scientific Sessions.

Original New Drug Application Approvals by US FDA (01 - 15 July 2019)

15 Jul 2019
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

XPOVIO
  • Active Ingredient(s): Selinexor
  • Strength: 20 mg
  • Dosage Form(s) / Route(s): Tablet; oral
  • Company: Karyopharm Therapeutics Inc.
  • Approval Date: 03 July 2019
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
  • Approved Label03 July 2019 (PDF)

KATERZIA
  • Active Ingredient(s): Amlodipine benzoate
  • Strength: 1 mg/mL
  • Dosage Form(s) / Route(s): Suspension; oral
  • Company: Silvergate Pharms
  • Approval Date: 08 July 2019
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): May be used alone or in combination with other antihypertensive and antianginal agents for the treatment of:
    • Hypertension: indicated for the treatment of hypertension in adults and children 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily stroke and myocardial infarctions.
    • Coronary Artery Disease: Chronic Stable Angina; Vasospastic Angina (Prinzmetal's or Variant Angina); Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40%.
  • Approved Label08 July 2019 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
A recent study has shown no improvement in the rate of blood pressure (BP) control despite an increase in the prevalence of antihypertensive medication use.
Roshini Claire Anthony, 11 Feb 2020

The consumption of processed meat or unprocessed red meat may be associated with a slightly elevated risk of incident cardiovascular disease (CVD)* and all-cause mortality, according to a US study.

29 Jan 2020
Several high-density lipoprotein (HDL) functionality parameters, which are linked to HDL roles on cholesterol metabolism, endothelial protection and antioxidant/anti-inflammatory defence, contribute to an increased risk of incident acute coronary syndromes and its manifestations in individuals at high risk of cardiovascular disease, a study reports.
Jairia Dela Cruz, 25 Nov 2019
Use of the PCSK9* inhibitor alirocumab in acute coronary syndrome (ACS) patients on a background of high-intensity statin treatment delivers reductions in total hospitalizations and death with corresponding gains in days alive and out of hospital (DAOH), according to the results of prespecified and posthoc analyses of the ODYSSEY OUTCOMES** trial presented at the American Heart Association (AHA) 2019 Scientific Sessions.